These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22361037)

  • 1. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations.
    Gurzu S; Jung I
    Pathol Res Pract; 2012 Mar; 208(3):163-6. PubMed ID: 22361037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.
    Bayrak R; Yenidünya S; Haltas H
    Pathol Res Pract; 2011 Mar; 207(3):156-60. PubMed ID: 21282015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.
    Gurzu S; Szentirmay Z; Toth E; Bara T; Bara T; Jung I
    PLoS One; 2013; 8(3):e57699. PubMed ID: 23469219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.
    Park SY; Kim HS; Hong EK; Kim WH
    Hum Pathol; 2002 Nov; 33(11):1078-85. PubMed ID: 12454811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
    Su YC; Hsu YC; Chai CY
    Kaohsiung J Med Sci; 2006 Jan; 22(1):14-9. PubMed ID: 16570563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability.
    McGregor DK; Wu TT; Rashid A; Luthra R; Hamilton SR
    Am J Surg Pathol; 2004 Jun; 28(6):712-8. PubMed ID: 15166663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].
    Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS
    Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors.
    Tot T
    Cancer; 1999 Jan; 85(1):171-7. PubMed ID: 9921990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubular carcinoids of the appendix: the CK7/CK20 immunophenotype can be a diagnostic pitfall.
    Matsukuma KE; Montgomery EA
    J Clin Pathol; 2012 Jul; 65(7):666-8. PubMed ID: 22461652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 7 and 20 expression in choroid plexus tumors: utility in differentiating these neoplasms from metastatic carcinomas.
    Gyure KA; Morrison AL
    Mod Pathol; 2000 Jun; 13(6):638-43. PubMed ID: 10874668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.
    Cai YC; Banner B; Glickman J; Odze RD
    Hum Pathol; 2001 Oct; 32(10):1087-93. PubMed ID: 11679943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
    Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
    Tot T
    Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
    Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and immunohistochemical study of 20 choroid plexus tumors: their histological diversity and the expression of markers useful for differentiation from metastatic cancer.
    Ikota H; Tanaka Y; Yokoo H; Nakazato Y
    Brain Tumor Pathol; 2011 Jul; 28(3):215-21. PubMed ID: 21394517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.